HIV and ID Observations

August 5th, 2018

Why Caring for People with HIV Is Still Great

Earlier this year, I wrote a piece about friends and colleagues of mine who have left HIV clinical practice. Something about it touched a nerve. It’s one of the most commented-on pieces in the history of this blog. Read this for a typical response. Admittedly, it was kind of a downer — but it might have been […]

---

July 22nd, 2018

FDA Approves First PI-Based Single-Tablet Treatment for HIV — How Will It Be Used?

The latest HIV drug approval from the FDA came this past week with the release of a single-tablet treatment containing the following drugs: Darunavir (DRV) 800 mg Cobicistat (c) 150 mg Emtricitabine (FTC) 200 mg Tenofovir alafenamide (TAF) 10 mg Often abbreviated “DCF-TAF,” this is the first full treatment regimen in a single pill with a […]

---

July 15th, 2018

On-Service Digest, July 2018 — with Special Section Just for Staph aureus

I’m currently on-service for the inpatient ID consult team, and this is July. At a teaching hospital.  Here’s where some would play scary music. After all, the interns and fellows have just started! YIKES! But no scary music for me — I love working with the July newbies. Because whatever they lack in experience or efficiency, they more than make up […]

---

July 8th, 2018

Surgeon Who Was Denied Disability Insurance for Taking PrEP Tells His Story

Earlier this year, urology resident Dr. Philip Cheng appeared on the front page of the New York Times. Here was the headline: He Took a Drug to Prevent AIDS. Then He Couldn’t Get Disability Insurance. The piece understandably drew widespread attention, with sharp disapproval of the denial from ID specialists and public health officials. We couldn’t […]

---

May 28th, 2018

Predatory Journals Are Such a Big Problem It’s Not Even Funny

I’ve made fun of academic spam numerous times on this site. It’s those emails from dubious “predatory journals,” written in cheerful but awkward prose, with flowery praise and open invitations to submit research on various scientific topics. You know, the emails that start: Dear Dr. Paul E. Greetings for the day! Most of my coverage has been on […]

---

May 20th, 2018

Why the Dolutegravir Pregnancy Warning Is Important — and What We Should Do Now

Last week, in response to newly available surveillance data, multiple agencies issued a warning about the HIV integrase inhibitor dolutegravir (DTG) and pregnancy. The warnings cite an increased risk of neural tube defects in babies born to women who became pregnant while receiving the drug. From the U.S. Department of Health and Human Services: The concern stems from […]

---

May 6th, 2018

Looking Back on a Decade of Blogging About HIV and Infectious Diseases

Last week, Dr. Wendy Armstrong from Emory kindly invited me to spend some time with their smart, energetic ID fellows. (See if you can pick me out of the group in the photo at right — hint, I’m the old guy on the left.) Before the trip, Wendy asked them whether they’d rather hear me give a […]

---

April 8th, 2018

Latest DHHS Guidelines for Initial HIV Therapy Now Include 5 Choices — But Really 2 Are Best

On March 28, the Department of Health and Human Services Guidelines issued an update to the HIV treatment guidelines, with a focus on the recent approval of bictegravir/TAF/FTC: BIC/TAF/FTC is an effective and well-tolerated INSTI-based regimen for initial therapy in adults with HIV, with efficacy that is noninferior to DTG/ABC/3TC and DTG plus TAF/FTC for up […]

---

March 11th, 2018

Really Rapid Review — CROI 2018, Boston

The 25th Conference on Retroviruses and Opportunistic Infections (CROI) just wrapped up in warm, sunny Boston. Everyone in attendance took advantage of the fine March weather to get some much-needed sun, to feel the sand between their toes, to sip a tropical drink, and to hear the latest in HIV research. Well, the last part was true […]

---

February 25th, 2018

Is Self-Administered Postexposure Prophylaxis Another Viable Option for HIV Prevention?

Most of the pivotal trials of pre-exposure prophylaxis (PrEP) have used daily therapy. The lone exception is the IPERGAY study. Men at high risk for acquiring HIV took two tablets of tenofovir DF/emtricitabine (TDF/FTC, Truvada) before sex, and one tablet the next 2 days. The strategy was highly effective in preventing HIV acquisition, and intermittent PrEP is endorsed […]

---